← board
GYRE
distress 1/10 · well-funded / low risk$5.88-1%today-34% from 52w high
Lead: MASH-associated liver fibrosis · est. market ~$5B (approx, global)
Revenue
$23M
Liquidity
$51M
Runway
—
Shares 1y
+1%
Price & events
-27.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.0%
1D
-8.4%
1W
-4.1%
1M
-21.0%
3M
-25.1%
6M
-22.3%
1Y
-61.4%
2Y
-44.1%
5Y
-60.9%
All
Overview
- Market Cap
- $570.53M
- Volume
- 1.84K
- 52 Week Range
- $5.56 – $8.87
- Total Shares
- 97.03M
- Float Shares
- 33.93M
- Short %
- 5.19%
- % Held by Insiders
- 86.33%
- % Held by Institutions
- 3.75%
- RVOL
- 0.02x
- Beta
- 4.78
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 17
- by the end of 2026Guided 40%regulatory submissionFiled (NDA/BLA)F351 · Plan to file IND in USSEC 8-K
- 2026-08-10earningsEarningsEarnings releaseyahoo
- first half of 2026regulatory submissionFiled (NDA/BLA)Hydronidone · Plan to submit NDA for conditional approval in ChinaSEC 8-K
- May 15, 2026conferencedata presentationsecondaryGyre Therapeutics presenting at scientific conference in ShanghaiSEC 8-K
- May 12, 2026filing acceptanceFiled (NDA/BLA)F351 · NDA accepted by China NMPASEC 8-K
- March 22, 2026regulatory submissionFiled (NDA/BLA)F351 · NDA submitted to CDE of China's NMPASEC 8-K
- now enrollingtrial initiationsecondaryPhase 2CG001419 · US Phase 2 pain trial for CG001419 now enrollingSEC 8-K
- 2026-03-02partnershipGyre enters into merger agreement to acquire Cullgen in all-stock transaction valued at approximately $300 million.SEC 8-K
- 2026-01-05fda agreementHydronidone · CDE agreed Phase 3 data support conditional approval filing and priority review eligibilitySEC 8-K
- 2H 2025trial initiationsecondaryPhase 2/3pirfenidone · Phase 2/3 trial anticipatedSEC 8-K
- 2H 2025trial initiationsecondaryPhase 2Hydronidone · Phase 2 trial in US expected to initiateSEC 8-K
- 4Q 2025trial initiationsecondaryPhase 2/3F528 · Start Phase 2/3 trialSEC 8-K
- 4Q 2025enrollment completesecondaryPhase 2F573 · Complete enrollment in Phase 2 trialSEC 8-K
- December 2025regulatory submissionFiled (NDA/BLA)F528 · plan to submit a new INDSEC 8-K
- Q3 2025regulatory submissionFiled (NDA/BLA)Hydronidone · NDA submission to NMPA for Hydronidone in ChinaSEC 8-K
- first quarter of 2025readoutPhase 3Hydronidone · topline data for Phase 3 trial in ChinaSEC 8-K
- by early 2025readoutPhase 3F351 · Topline data readout for Phase 3 trial of F351 in CHB-associated liver fibrosisSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2025-10-10JefferiesBuy
- 2025-08-26HC Wainwright & Co.Buy
Competitors — MASH-associated liver fibrosis
- none identified
Recent news
- 2026-07-18Gyre Therapeutics Strengthens Board with New Director Appointments - The Globe and Mail
- 2026-07-17Gyre Therapeutics Strengthens Board with New Director Appointments - TipRanks
- 2026-07-16Gyre Therapeutics appoints three directors to board - Investing.com
- 2026-07-16Gyre Therapeutics (Nasdaq: GYRE) adds three directors, expanding expertise - Stock Titan
- 2026-07-16Gyre Therapeutics Appoints Three New Members to its Board of Directors - The Manila Times
- 2026-07-16Gyre Therapeutics Appoints Three New Members to its Board of Directors - The Manila Times
- 2026-07-16Gyre Adds Director With Drug Development Experience Across China, Japan - Stock Titan
- 2026-07-16Gyre Therapeutics, Inc. Announces Board and Committee Changes, Effective August 1, 2026 - marketscreener.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.